Oruka Therapeutics CMO Joana Goncalves Buys 7,000 Shares

On June 15, 2026, Joana Goncalves, the Chief Medical Officer of Oruka Therapeutics, Inc., made a notable purchase of 7,000 shares of the company's stock. She bought the shares at an average price of $7.32, bringing the total transaction value to $51,240. This insider purchase was not part of a pre-arranged trading plan.

Insider Buying and Selling at Oruka Therapeutics, Inc.

Joana Goncalves wasn't the only insider active on June 15. She also sold 3,500 shares the same day. Other executives, including Laura Lee Sandler, the Chief Operating Officer, and Arjun Agarwal, the Senior Vice President of Finance, also sold shares. Sandler sold 600 shares, while Agarwal sold 395 shares under a planned transaction. Paul Quinlan, the General Counsel, sold 733 shares.

Other Institutional Activity in Oruka Therapeutics

Several institutional investors have recently adjusted their positions in Oruka Therapeutics. FMR LLC increased its holdings by 170,019 shares, ending with 7,431,403 shares worth about $364.5 million. VENROCK ADVISER, LLC maintained its position with 4,148,428 shares valued at approximately $203.5 million. Meanwhile, BlackRock, Inc. reduced its holdings by 12,328 shares, leaving it with 3,527,087 shares valued at roughly $173 million. Paradigm Biocapital Advisors LP made a significant increase, adding 610,000 shares to hold a total of 2,320,316 shares worth $113.8 million.

Oruka Therapeutics Stock Snapshot

Shares of Oruka Therapeutics, trading under the ticker ORKA on NasdaqGM, were last seen near $69.89. The company has a market capitalization of about $4.22 billion. It operates with a forward P/E ratio of -28.39, indicating a lack of profitability. The stock's 52-week range spans from a low of $10.77 to a high of $91.00. Oruka's 50-day moving average is $63.70, while its 200-day moving average is $37.60. The company's financial health appears strong with a current ratio of 23.76 and a quick ratio of 23.38.

Analysts Set New Price Targets

Analysts remain bullish on Oruka Therapeutics. On May 14, 2026, BTIG reiterated its 'buy' rating with a price target of $151. Previously, on April 29, HC Wainwright & Co. maintained its 'buy' rating with a target of $120. UBS and Barclays also maintained 'buy' ratings with targets of $100 and $160, respectively. The consensus among 12 analysts is a 'strong buy' with an average price target of $142.17.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Menlo Park, California. It focuses on developing innovative monoclonal antibody treatments for psoriasis and other inflammatory and immunology conditions. The company is led by CEO Dr. Lawrence Otto Klein and employs 68 people. Oruka's leading products include ORKA-001 and ORKA-002, both in phase 2 trials for various inflammatory conditions.

Bottom Line

Joana Goncalves's purchase of Oruka shares reflects her confidence in the company's prospects. While insider transactions can offer insights, they are just one piece of the puzzle for investors. Oruka's stock is on a strong trajectory, supported by positive analyst sentiment and robust institutional interest. As always, it's essential to consider the broader market context and company fundamentals.